Role of the new family of tumor-specific proteins FAM83 in thyroid cancer

• Grant number: 13/11019-4
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2014
• End date: July 31, 2016
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Edna Teruko Kimura
• Grantee: Edna Teruko Kimura
• Host Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Papillary thyroid cancer (PTC) is the most common histotype of thyroid cancer whose incidence has been rising progressively in the last decade. The most prevalent genetic alteration in PTC is BRAF mutation (BRAFT1799A), detected in more than 45% of patients. This mutation activates constitutively MAPK pathway, and moreover, amplify other signaling pathways involved in cell proliferation, migration, invasion and apoptosis, favoring thyroid oncogenesis. However, the understanding of additional molecular events associated with differential behavior within the same background tumors, leading to an aggressive outcome, is yet incomplete. To this extent, our group has identified in the Human Genome Cancer Project (FAPESP/LICR) the unknown function LOC113828 located at chromossome 22 in human that was recently renamed as FAM83F gene. The family of FAM83 is composed by eight members, from FAM83A to FAM83H, that share the conserved aminoterminal DUF1699 with unknown function. In recent studies, increased expression of FAM83A and FAM83B has been detected in several types of tumors in association with therapy refractoriness, indicating the involvement of this family in this process. Data from our lab shows that PTC displays increased levels of FAM83F and, thus, we expect that the in vitro and in vivo study of FAM83 family function could contribute to the knowledge of progression and in the understanding of tumoral heterogeneity.in the thyroid cancer. (AU)

Scientific publications

(7)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

FUZIWARA, CESAR SEIGI; KIMURA, EDNA TERUKO. MicroRNAs in thyroid development, function and tumorigenesis. Molecular and Cellular Endocrinology, v. 456, n. C, SI, p. 44-50, NOV 15 2017. (16/17129-4, 13/11019-4, 14/50521-0)

GERALDO, MURILO V.; KIMURA, EDNA T.. Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators. PLoS One, v. 10, n. 11, NOV 4 2015. (13/11019-4, 11/52051-2)

FUZIWARA, CESAR SEIGI; KIMURA, EDNA TERUKO. Insights into regulation of the miR-17-92 cluster of miRNAs in cancer. FRONTIERS IN MEDICINE, v. 2, 2015. (13/11019-4, 14/50521-0)

FUZIWARA, CESAR SEIGI; KIMURA, EDNA TERUKO. MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2014. (13/11019-4)

FUZIWARA, CESAR SEIGI; SAITO, KELLY CRISTINA; LEONI, SUZANA GARCIA; LOGULLO WAITZBERG, ANGELA FLAVIA; KIMURA, EDNA TERUKO. The Highly Expressed FAM83F Protein in Papillary Thyroid Cancer Exerts a Pro-Oncogenic Role in Thyroid Follicular Cells. FRONTIERS IN ENDOCRINOLOGY, v. 10, MAR 1 2019. (16/17129-4, 13/11019-4, 14/50521-0)

FUZIWARA, CESAR SEIGI; KIMURA, EDNA TERUKO. MicroRNAs in thyroid development, function and tumorigenesis. Molecular and Cellular Endocrinology, v. 456, n. C, p. 7-pg., 2017-11-15. (16/17129-4, 14/50521-0, 13/11019-4)

FUZIWARA, CESAR SEIGI; KIMURA, EDNA TERUKO. MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, v. 2014, p. 8-pg., 2014-01-01. (13/11019-4)